EDIT (Editas Medicine) Interest Expense: $-5.03 Mil (TTM As of Mar. 2026)

What is Editas Medicine Interest Expense?

Editas Medicine EDIT +1.89% 51 Interest Expense is $-5.03 Mil as of Mar. 2026. GuruFocus rates EDIT with a GF Score™ of 51/100 and a GF Value™ of $1.92 (Significantly Overvalued). The stock has 10 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Editas Medicine's interest expense for the three months ended in Mar. 2026 was $ -1.07 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was $-5.03 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Editas Medicine's Operating Income for the three months ended in Mar. 2026 was $ -25.00 Mil. Editas Medicine's Interest Expense for the three months ended in Mar. 2026 was $ -1.07 Mil. Editas Medicine did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Editas Medicine (NAS:EDIT) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Editas Medicine's Interest Expense for the three months ended in Mar. 2026 was $-1.07 Mil. Its Operating Income for the three months ended in Mar. 2026 was $-25.00 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was $10.60 Mil.

Editas Medicine's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Editas Medicine did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Editas Medicine Interest Expense Historical Data

* Premium members only.

The historical data trend for Editas Medicine's Interest Expense can be seen below:

Editas Medicine Interest Expense Chart

Editas Medicine Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Interest Expense

Get a 7-Day Free Trial

0.00

-2.19

-6.17

Editas Medicine Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Interest Expense	Get a 7-Day Free Trial															-2.22	-2.02	-2.40	0.46	-1.07

51GF Score

Editas Medicine Inc EDIT

Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Editas Medicine Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.03 Mil.

Frequently Asked Questions Learn more about Interest Expense →

What does a Interest Expense of $-5.03 Mil mean?

Editas Medicine (EDIT) has a Interest Expense of $-5.03 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Editas Medicine and its competitors.

Is Editas Medicine's Interest Expense too high?

Editas Medicine's current Interest Expense is $-5.03 Mil. Overall, Editas Medicine has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Editas Medicine's Interest Expense compare to SGMT and AUTL?

Editas Medicine's Interest Expense of $-5.03 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Interest Expense for a Biotechnology company?

A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Interest Expense mean?

A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Editas Medicine and its competitors. Editas Medicine's current Interest Expense is $-5.03 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Editas Medicine stock overvalued right now?

Based on GuruFocus' analysis, Editas Medicine (EDIT) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.92, compared to a current price of $3.25 — trading 69% above its estimated fair value. The current Interest Expense is $-5.03 Mil. Editas Medicine's overall GF Score™ is 51/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Interest Expense calculated?

Interest Expense is calculated from a company's financial statements. For Editas Medicine (EDIT), the current Interest Expense is $-5.03 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Editas Medicine (EDIT) Overvalued in 2026?

Based on GuruFocus' analysis, Editas Medicine stock appears to be overvalued. The current stock price of $3.25 is trading 69% above its estimated GF Value™ of $1.92. GuruFocus considers Editas Medicine to be Significantly Overvalued.

Key valuation signals for EDIT:

Interest Expense: $-5.03 Mil
GF Value™: $1.92 vs. price of $3.25 (69% above fair value)
GF Score™: 51/100 with 10 warning signs

No single metric tells the full story. See the EDIT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Editas Medicine Business Description

Industry Healthcare Biotechnology

Comparable Companies SGMT AUTL FBRX INDP BNTC IPSC PBYI ARTV ENTA OVID VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges 0IFK:UK 8EM:Germany

Address 11 Hurley Street, Cambridge, MA, USA, 02141

Website https://www.editasmedicine.com

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.

51GF Score

Get the complete analysis for EDIT

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.25

Price

$1.92

GF Value

View EDIT Analysis

See Interest Expense data for all stocks →